INTENSIVE PK SUBSTUDY OF ACTG359-SAQUINAVIR IN COMBINATION W/ RITONAVIR IN HIV+

300例HIV感染者的随机、半盲、多中心研究 病毒载量> 2000且<200，000拷贝HIV RNA/mL的受试者， 已使用茚地那韦至少6个月，茚地那韦稳定， 治疗前至少四周接受抗逆转录病毒治疗， 研究入口。 研究的主要目的是评估和 比较6种治疗方案中血浆 HIV-1 RNA在开始治疗后16周<500拷贝/ml， 评价治疗方案的安全性、毒性和耐受性。 治疗将持续24周，可选择延长24周， 病毒载量<5，000 copies/ml或至少低于一个log 的基线值。 ACTG 884是一项强化药理学子研究， ACTG359。 强化药理学子研究的目的是确定 在每一种药物中，个体药物的稳态全身暴露量 六个治疗臂。

A randomized, partially-blinded, multicenter study for 300 HIV infected subjects with viral loads of _> 2000 and <_ 200,000 copies HIV RNA/mL who have been on indinavir for at least six months wtih stable, indinavir- containing anti-retroviral therapy for at least four weeks prior to the study entry. The primary ojbectives of the study are to evaluate and compare the six treatment regimens for proportion of subjects whose plasma HIV-1 RNA is <500 copies/ml 16 weeks after starting treatment and to evaluate the safety, toxicity and tolerance of the treatment regimens. Treatment will last 24 weeks with an option for 24 weeks extension for those whose viral load is < 5,000 copies/ml or at least one log below their baseline value. ACTG 884 is an Intensive Pharmacology Substudy of ACTG359. The goal of the Intensive Pharmacology Substudy is to determine the steady-state systemic exposure of the individual agents in each of the six treatment arms.